Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Cancer Res. 2019 Jul 23;79(19):5102–5112. doi: 10.1158/0008-5472.CAN-18-3882

Figure 3. All pathways are significantly dysregulated in immune cell types from breast tumors relative to normal breast tissue.

Figure 3.

Boxplot of EVA statistics of inter-cellular heterogeneity for all 50 hallmark pathways in major immune cell types from both tumor (blue) and normal (red) breast tissue.